Foundation for Innovative New Diagnostics Find

“Form 990 review process the form 990 is prepared by an independent accounting firm and reviewed by the director of finance. Once approved by the director of finance, the form 990 is also reviewed by the ceo. Additionally, in 2019 find participated in a benchmarking exercise with peer organization to ensure consistency of treatment of various items on form 990.”

“FIND's conflict of interest policy requires directors, officers and key employees, all other staff members, board members consultants and partners to disclose actual or potential conflicts of interest when they arise. The person or company is also required to recuse themselves from any decision making.”

“COMPENSATION REVIEW AND APPROVAL PROCESS A review by an independent consultant of the CEO's remuneration package was done by the Board and forms the basis of written employment contract. Remuneration terms for officers and key employees are based on market rates for similar positions in specific locations. This benchmarking is done against an independent report which presents data collected for similar organizations and this exercise is done every 3 years. Salaries for all staff are available to the Board and Compensation Committee. However, the salaries of the C-suite and other key staff are approved by the Compensation Committee.”

“AVAILABILITY OF GOVERNING DOCUMENTS TO THE PUBLIC FIND's governing documents (Statutes and By-Laws) Conflict of Interest policy and Financial Statements are available for inspection at FIND's offices in Geneva upon request.”

“Books in care of phone number The telephone number of the person who possesses the books and records is: +41 (22) 710 05 90.”

“The organization's telephone number is +41 (22) 710 05 90.”

“NEW PROGRAM SERVICES In response to the Covid-19 pandemic, FIND has responded with a new program stream, Covid-19 and pandemic preparedness. The details of the program are described in Part III Line 4.”

“other program SERVICES program services for Access, Fever & Malaria, HCV & HIV, and Neglected Tropical Diseases. A summary of each program is given below. PROGRAM - Access: Expenses - $15,437,143 including grants $3,183,085 Program scope is broad with multiple focus areas that will ultimately enable access to testing. For India, 2020 included COVD-19 response work (testing, sequencing, reagent development). With traditional TB programs at risk, we worked to strengthen bi-directional screening. Despite COVID, TB lab work continued - Karnataka became India's first state where all three Intermediate Reference Laboratories achieved ISO accreditation. EQA methods were established in >1,100 sites, and quality TB care services extended to private sector patients (~190,000 patients notified >82% successful treatment outcomes reported in a 3-month period). We also continued to work on micro-elimination of HCV in prisons and had two community-based delivery model projects running in India. These projects (another is in Senegal) target TB and diabetes as a leading co-morbidity factor for TB patients, cater to rural communities and leverage existing networks, such as women-led community groups. Diagnostic network optimization (DNO) was carried out in Central African Republic, the Gambia, India, and Rwanda. DNO analysis that matches testing demand with testing capacity increases access, improves efficiency, and develops routing for specimen referral networks. This project was adapted to respond to COVID-19 testing demands. PROGRAM - Fever & Malaria: Expenses - $4,052,356 including grants of $2,098,277 The work for malaria targets tools to meet one of the few remaining diagnostic gaps in malaria, specifically robust tools to use in P. vivax malaria elimination. For fever, our primary focus is tools for differential diagnosis of patients who present with fever at the primary healthcare level where studies have confirmed ~90% of patients with a negative malaria test received antibiotics, fueling anti-microbial resistance. PROGRAM - HCV and HIV: Expenses - $6,442,490 including grants of $3,679,160 The work was for HCV only, and bulk of 2020 work was on 1) sampling methods that eliminate cold chain needs, critical for increasing access to testing at lower levels of the healthcare system; it also allows for integration into existing HIV DBS systems; and 2) evaluation of self-testing that includes using portable molecular diagnostics shown that this approach can help overcome apathy towards testing and mitigate barriers to clinic based testing. PROGRAM - NTDs: Expenses - $5,055,970 including grants of $2,955,599 FIND works on five different NTDs: Chagas disease, Buruli ulcer, sleeping sickness, visceral leishmaniasis and schistosomiasis. Work in each of these disease areas is shaped to address primary gaps in elimination strategies, for example for HAT, in 2020 we started shaping our ongoing R&D and large-scale country projects to be in line with changing elimination strategies and supply challenges (which is a common problem for tests for NTDs). Form 990, Part V, Line 2a and Part VII, Section A Individuals employed by the FIND are not U.S. Residents or U.S. employees. Information pertaining to the number of employees and employee compensation is provided using the best information available from equivalent W-2 and W-3 Forms for the various countries in which the FIND employs individuals.”